Switching to Nexviazyme stabilizes or improves lung function in LOPD
Switching from Lumizyme (alglucosidase alfa) to Nexviazyme (avalglucosidase alfa) stabilizes or improves lung function in people with late-onset Pompe disease (LOPD). That’s according to new analyses from the COMET Phase 3 clinical trial and its open-label extension study, which showed the benefits of switching to Nexviazyme were…